-transparent.png){kind=logo}
To investigate the efficacy and the safety of RU23908 for the treatment of prostatic cancer, an early phase 2 study with the oral administration of 150 or 300 mg daily was performed in 47 patients with stage C or D prostatic cancer at 15 institutions from April 1987 to June 1988. Forty patients were evaluable for efficacy. Concerning the effect on the object lesion, the results of the overall evaluation revealed that complete or partial response (CR + PR) was obtained in 34 of the 40 cases (85.0%). As to the effect classified by site, CR + PR were observed in 35 out of the 40 cases with primary lesion (87.5%), in 10 of the 22 cases with bone metastasis (45.5%), in 5 of the 6 cases with lymph node metastasis (83.3%) and CR was observed in one case with lung metastasis. In the PAP evaluation, 33 out of the 34 cases were judged to be CR + PR (97.1%). The improvement rate of clinical symptoms was 88.9% for bone pain, 83.3% for dysuria and 45.5% for performance status. Adverse reactions were observed in 29 of the 47 cases (61.7%) investigated and 7 cases (14.9%) were withdrawn. During the study period of 12 weeks and the subsequent period of continued administration, 6 cases (12.8%) and 2 possible cases of interstitial pneumonia were diagnosed. From the above results, the treatment of prostatic cancer with RU23908 150 mg/day or 300 mg/day in combination with surgical castration showed an excellent clinical effect compared to conventional endocrine therapy, but has a problem of safety. Therefore, this drug may be expected to be a highly useful therapeutic drug, if safely is improved in the future by reviewing the dose.
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1985,
Progress in clinical and biological research,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
May 1991,
British journal of cancer,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1987,
Progress in clinical and biological research,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1991,
Cancer detection and prevention,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1984,
The Prostate,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1991,
European journal of cancer (Oxford, England : 1990),
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
January 1988,
American journal of clinical oncology,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
July 1979,
Journal of steroid biochemistry,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
November 1988,
Cancer research,
H Akaza, and
Y Aso, and
T Niijima, and
H Fuse, and
S Izaka, and
S Akimoto, and
J Shimazaki, and
K Imai, and
H Yamanaka, and
K Kihara
August 1989,
Hinyokika kiyo. Acta urologica Japonica,
